Canadian Pharmacy

Canada Pharmacy - Reliable Canadian Generics Supplier.

Check yourbonu$
Site search:
Obvious advantage Tell a friend and get discount! Want to give it a try?
Categories list
index
Search by letter:ABCDEFGHIJKLMNOPQRSTUVWXYZ
Casodex

Generic Casodex

Bicalutamide 50mg

Treating prostate cancer.Bicalutamide...
Generic Casodex

$4.65 Buy now!
Choose Your language:
Social bookmarks:
Testimonials

Thank you for your mail. Yes, I received my order and everithing is fine with it. Thank you very much for the four extra pills you had, I really do appreciate it. I should recommand your site to friends and I'll come back to you soon.

Our billing is certified by:

Secure shopping certificates


Special Offer!

secure shopping online
money back guaranteed
News

  • Medivation Reports First Quarter Financial Results and Provides Corporate Update - MarketWatch (press release)

    Medivation Reports First Quarter Financial Results and Provides Corporate UpdateMarketWatch (press release)Continued to enroll patients in the Phase 2 TERRAIN trial, which is comparing the effect of enzalutamide versus bicalutamide, the most commonly used anti-androgen, on progression-free survival in approximately 370 men with advanced prostate cancer who .

  • MDVN Misses; Focus on Enzalutamide - Zacks.com

    MDVN Misses; Focus on EnzalutamideZacks.

  • New Therapies for Prostate Cancer: The Practicalities - OncLive

    OncLiveNew Therapies for Prostate Cancer: The PracticalitiesOncLive12,13 This investigational agent is an irreversible androgen receptor (AR) antagonist and AR signaling inhibitor, and represents an advance from the nonsteroidal AR antagonists flutamide, bicalutamide, and nilutamide.

  • MDVN Misses; Focus on Enzalutamide - Analyst Blog - NASDAQ

    MDVN Misses; Focus on Enzalutamide - Analyst BlogNASDAQEnzalutamide is also in a phase II study (TERRAIN), which will compare enzalutamide with bicalutamide, in advanced prostate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration.

  • CEO Brennan to leave AstraZeneca as profits sink - Pharma Times

    CEO Brennan to leave AstraZeneca as profits sinkPharma TimesAs for oncology, Arimidex (anastrozole) fell 39% to $144 million, battered by patent expiries, while Casodex (bicalutamide) fell 17% to $113 million.

bookmark Bookmark this site
subscribe Subscribe to the News
Canadian Pharmacy Trusted Rx approved.